Dyslipidemia in patients with chronic kidney disease (Q39045120)

8 September 2017

Dyslipidemia in patients with chronic kidney disease (English)

1 reference

8 September 2017

1 reference

Matthew R Hager

1

1 reference

PubMed ID

28000009

8 September 2017

Archana D Narla

series ordinal

2

1 reference

PubMed ID

28000009

8 September 2017

Lisa R Tannock

series ordinal

3

1 reference

8 September 2017

20 December 2016

1 reference

Reviews in Endocrine and Metabolic Disorders

8 September 2017

1 reference

8 September 2017

18

1 reference

8 September 2017

29-40

1 reference

8 September 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1007/s11154-016-9402-z

8 September 2017

0 references

cites work

Cholesterol Metabolism in CKD

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Trends in Prevalence of Chronic Kidney Disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Lipid disorders and their relevance to outcomes in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Cardiovascular risk factors and incident acute renal failure in older adults: the cardiovascular health study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Cardiovascular risk prediction in people with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: comparison with apoprotein CIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

The atherogenic lipoprotein phenotype: small dense LDL and lipoprotein remnants in nephrotic range proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Lipid and lipoprotein metabolism in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Effects of hemodialysis on serum lipids and phospholipids of end-stage renal failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Association between serum lipids and survival in hemodialysis patients and impact of race

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Reduction in cardiovascular risk by sodium-bicarbonated mineral water in moderately hypercholesterolemic young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Effect of deferoxamine therapy on insulin resistance in end-stage renal disease patients with iron overload.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Apolipoprotein E-knockout mice on high-fat diet show autoimmune injury on kidney and aorta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: its safety in a combination with oral calcium carbonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Inhibition of apolipoprotein AI gene expression by 1, 25-dihydroxyvitamin D3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Inhibition of intestinal cholesterol absorption by ezetimibe in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Effects of extended-release niacin with laropiprant in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Mechanism of action of fibrates on lipid and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Effects of fibrates in kidney disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Omega-3 and renal function in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Nonstatin therapies for management of dyslipidemia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

PCSK9 inhibitors - mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

Effect of metabolic acidosis on hyperlipidemia in uremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-016-9402-Z

High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients

21 January 2018

1 reference

12 December 2020

Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation

1 reference

12 December 2020

Renal and vascular protective effects of ezetimibe in chronic kidney disease

1 reference

12 December 2020

Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients

1 reference

12 December 2020

Lower serum high-density lipoprotein-cholesterol concentration in patients undergoing maintenance hemodialysis with acetate than with bicarbonate

1 reference

12 December 2020

Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin

1 reference

12 December 2020

More hostile dyslipidaemia in chronic kidney disease patients on maintenance haemodialysis than on conservative management

1 reference

12 December 2020

Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure

1 reference

12 December 2020

Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet

1 reference

12 December 2020

The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients

1 reference

12 December 2020

Alterations in lipoprotein composition in peritoneal dialysis patients

1 reference

12 December 2020

Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients

1 reference

12 December 2020

Relation of cyclosporine blood levels to adverse effects on lipoproteins

1 reference

12 December 2020

Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data

1 reference

12 December 2020

Renal handling of human apolipoprotein(a) and its fragments in the rat

1 reference

12 December 2020

Effects of erythropoietin therapy on the lipid profile in end-stage renal failure

1 reference

12 December 2020

In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients

1 reference

12 December 2020

Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation

1 reference

12 December 2020

Lipoprotein (a) in chronic renal failure: effect of maintenance hemodialysis

1 reference

12 December 2020

10.1007/S11154-016-9402-Z

Identifiers

DOI

1 reference

8 September 2017

1 reference

PubMed ID

28000009